Cover Image
市場調查報告書

疫苗受託製造市場 (2016-2026年)

Vaccine Contract Manufacturing Market, 2016 - 2026

出版商 ROOTS ANALYSIS 商品編碼 362820
出版日期 內容資訊 英文 265 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
疫苗受託製造市場 (2016-2026年) Vaccine Contract Manufacturing Market, 2016 - 2026
出版日期: 2016年06月29日 內容資訊: 英文 265 Pages
簡介

本報告提供疫苗製造專門的受託製造商 (CMO)的趨勢調查,疫苗概要,種類,組成,開發、製造工程,主要已開發國家、新興國家的疫苗受託製造市場變化與預測,各利用的表現系統的明細,主要疫苗CMO簡介,SWOT分析,未來展望等彙整資料。

第1章 序文

第2章 摘要整理

第3章 簡介

  • 本章概要
  • 疫苗的分類:各有效成分
    • 減毒活病毒疫苗
    • 不活化疫苗
    • 次單元疫苗
    • 類毒素疫苗
    • DNA疫苗
  • 疫苗的組成:主要零組件
    • 佐劑
  • 疫苗的開發、製造
    • 特定抗原和製造流程的開發
    • 製造流程
    • 臨床開發與核准
  • 受託製造:定義

第4章 競爭環境

  • 本章概要
  • 各地區的分析
  • 經營各規模分析
  • 利用的表現系統分別分析
  • 性能能力分別分析

第5章 疫苗受託製造:先進地區

  • 本章概要
  • 一站式服務:疫苗受託製造的成長趨勢
  • 美國的疫苗的外包
  • 美國的疫苗受託製造市場預測
  • 美國的疫苗受託製造市場預測:各利用的表現系統的分佈
  • 美國的主要疫苗CMO
    • AMRI / OsoBio
    • Catalent
    • Charles River Laboratories
    • Lonza
    • Meridian Life Science (MLS)
    • SAFC (A Unit of Sigma-Aldrich Corporation)
  • 歐洲的疫苗的外包
  • 歐洲的疫苗受託製造市場預測
  • 歐洲的疫苗受託製造市場預測:各利用的表現系統的分佈
  • 歐洲的主要疫苗CMO
    • Cobra Biologics
    • Eurogentec
    • IDT Biologika
    • SynCo Bio Partners

第6章 疫苗受託製造:新興地區

  • 本章概要
  • 中國的疫苗受託製造
    • 法律制度
    • 主要課題
    • 投資、產業的擴張
  • 中國的疫苗受託製造市場預測
  • 中國的疫苗受託製造市場預測:各利用的表現系統的分佈
  • 中國的主要疫苗CMO
    • GreenPak Biotech
    • Hong Kong Institute of Biotechnology
    • WuXi AppTec
  • 印度的疫苗受託製造
    • 法律制度
    • 主要課題
  • 印度的疫苗受託製造市場預測
  • 印度的疫苗受託製造市場預測:各利用的表現系統的分佈
  • 印度的主要疫苗CMO
    • Bharat Biotech
    • Biological E

第7章 近幾年的發展

  • 本章概要
  • 疫苗受託製造市場:聯盟
    • 各種聯盟的擴大趨勢
    • 各聯盟類型分析
    • 聯盟的重要度分別分析
  • 疫苗受託製造市場:設備製造能力的擴大

第8章 市場預測

  • 本章概要
  • 預測主要
  • 疫苗受託製造市場預測
  • 疫苗受託製造市場:地區分佈
  • 疫苗受託製造市場:各利用的表現系統的分佈

第9章 SWOT分析

第10章 未來趨勢

  • 本章概要
  • 創新的技術推動市場
  • VLP的出現
  • 細胞培養培養基的最佳化
  • 由於需求的擴大的追加投資的可能性
  • 策略性聯盟的轉變
  • 小規模經營者的收購

第11章 總論

第12章 採訪

第13章 附錄I:表格資料

第14章 附錄II:企業、組織清單

圖表

目錄
Product Code: RA10062

Vaccines have always been viewed as a low-margin business characterized by high entry barriers. Developmental and production related complexities, combined with significant fixed costs and stringent regulatory standards,have limited competition among vaccine manufacturers. In addition, these complexities have also restricted innovation in this space to a great extent. However, recent advances in biotechnology and biomanufacturing have resulted in the development of advanced technologies capable of addressing the challenges associated with manufacturing vaccines. Previously, the vaccine market was solely focused on preventive vaccines developed against infectious diseases. The advent of therapeutic vaccines has renewed interest in this field by paving way for vaccines to be developed for a variety of chronic and degenerative diseases. This has led to the entry of a number of established and emerging stakeholders who are competing for a share in this growing market segment.

It is well-known that the overall trend of outsourcing has grown significantly in the biopharmaceuticals industry. Due to the complex nature of vaccine development and manufacturing processes, both large and small stakeholders are exploring outsourcing opportunities for their products. Operational and infrastructural cost-benefits and reduced time-to-market are the major factors driving outsourcing. Manufacturing vaccines requires specialized resources and highly regulated technology platforms, which are becoming increasingly difficult to establish in-house. Although big pharma players prefer to carry out most of these processes in-house, they are gradually entering into long-term partnerships with trusted contract manufacturing organizations (CMOs). On the other hand, smaller and emerging players have been known to outsource a relatively larger share of their clinical development and commercial manufacturing processes to contract manufacturing partners. The landscape is rapidly evolving. CMOs aiming to consolidate their presence in the market are expanding their service portfolios to provide end-to-end services to their clients and sponsors.

The "Vaccine Contract Manufacturing Market, 2016 - 2026" report provides an extensive study of the current market landscape of CMOs focused on vaccines. The study presents an in-depth analysis of a diverse set of biopharmaceutical CMOs based on key parameters such as geographical location, scale of operation, use of expression systems and manufacturing capabilities. In addition, it captures some of the potential growth areas that will likely present tremendous opportunities for vaccine CMOs and contribute to an accelerated pace of growth.

The report assesses the key drivers that have governed the evolution of vaccine contract manufacturing market over the past several years, along with an elaborate discussion on the future trends that are likely to shape the market in the coming years. One of the focus areas of this study is to estimate size of the future opportunity for vaccine CMOs market over the next decade, segmented on the basis of business operations, type of expression systems and key regions.

The study also provides information on some of the most important aspects of vaccine outsourcing; these include growing collaborations, investment activity, facility expansions and technological advances. In addition to some of the well-known benefits and a promising outlook, the study highlights considerable challenges that are currently prevalent in the market. Examples include quality concerns, stringent regulations and lack of funding. Nevertheless, these challenges are resulting in new strategies and technological improvements, which are likely to prove advantageous in the long run.

The base year for the report is 2016; it provides market forecasts for the period 2016 - 2026. The research, analysis and insights presented in this report is backed by a deep understanding of key insights gathered both from secondary and primary research.

Example Highlights

  • 1. Vaccine development and manufacturing, characterized by complex production processes and high entry barriers, is set in a highly regulated market landscape. Outsourcing has emerged as a rising trend in this domain and gained a lot of traction in the last few years. As the market continues to evolve, CMOs are rapidly enhancing their service offering to offer end-to-end services to their clients.
  • 2. Developed regions, such as North America and Europe, currently dominate the vaccine contract manufacturing market. Of the 79 CMOs we identified, 41 have presence in multiple locations in the US. In Europe, the other major hub for CMOs, 20 CMOs have facilities located in Germany, France and the UK alone.
  • 3. CMOs in emerging locations have also gained ground. With increasing support from local governments, many low-income geographies have restructured their indigenous regulatory landscape. Intellectual property protection laws have been made more stringent in favor of foreign sponsors looking to outsource business operations in the same regions. Established players in this market have also received the necessary qualifications and certifications to provide services in compliance with global standards.
  • 4. Out of 79 CMOs, 21 offer end-to-end services across preclinical, clinical and commercial scale. We observed a rapid adoption of mammalian and insect production technologies among service providers.
  • 5. The highly competitive market landscape is abuzz with partnership activity. We have identified 128 unique partnerships that were inked in the recent past. Of these, a sizeable proportion (25%) is mergers / acquisitions. We believe this trend is likely to continue in the future.
  • 6. Technological advances are amongst the major driving factors in this market. The introduction of novel expression systems, such as the EB66® and GPEx® cell lines, and cell culture media platforms have sustained the interest of players in this field. Single use / disposable technologies, a key bio-manufacturing trend, are also becoming more and more popular among contract manufacturers. This is representative of the current market intensity.
  • 7. Driven by increasing global demand and the rapidly expanding vaccine market, we expect the overall contract manufacturing market in this space to grow at an annualized rate of 9.8%. The rate of growth is likely to vary significantly across different segments / activities and across geographical regions.

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the key insights captured in our research. The summary offers a high level view on the current status of the vaccine contract manufacturing market and where it is headed in the mid-long term.

Chapter 3 is a general introduction to vaccines. The chapter also includes an overview of the various expression systems used in the development of different vaccines and their related manufacturing procedures. It also provides an elaborate discussion on the need for outsourcing vaccine development and manufacturing processes. In this chapter, we have also presented a list of commonly outsourced biomanufacturing activities that we came across during the course of our research. The chapter also features a section dedicated to the challenges associated with the market.

Chapter 4 provides a comprehensive overview of the global landscape of vaccine CMOs. The chapter includes in-depth analysis based on regional distribution, scale of operation, manufacturing capabilities, type of vaccines manufactured and expression systems used.

Chapter 5 features an analysis of the trends, regulatory landscape and highlights the key players in vaccine contract manufacturing located in the US and Europe, the two leading geographies in this market. The chapter also provides a sub-market forecast for vaccine contract manufacturing segmented on the basis of expression systems used.

Chapter 6 provides details of vaccine contract manufacturing activities in China and India. It includes information on the regulatory framework, growth drivers and challenges associated with vaccine contract manufacturing in these regions. It also provides a high-level view on the production capabilities of some the key players in these emerging geographies. Additionally, a sub-market forecast for vaccine contract manufacturing segmented on the basis of expression systems used is also included in this chapter.

Chapter 7 presents an analysis of the recent developments in the vaccine contract manufacturing market. It provides a listing of the partnerships established in the recent past, along with an overview of other observed market trends, including investments and facility expansions.

Chapter 8 presents a detailed market forecast for the vaccine contract manufacturing market. Additionally, we have analyzed the future potential for specific geographies across the globe and in terms of the type of expression systems used. To account for the uncertain nature of the market, we have presented three different tracks of market evolution, namely the conservative, base and optimistic scenarios.

Chapter 9 provides a SWOT analysis capturing the key elements that are likely to influence the market's future.

Chapter 10 highlights future trends that are likely to emerge in the evolving vaccine contract manufacturing market. It includes brief discussions on important aspects such as the adoption of innovative technologies and a shift to strategic partnering. The chapter also addresses the growing market demand and how it is likely to influence the future growth and evolution of this market.

Chapter 11 is a summary of the entire report. It providesthe key takeaways and presents our independent opinion of the vaccine CMOs market, based on the research and analysis described in the previous chapters.

Chapter 12 contains the transcripts of interviews conducted with representatives from renowned organizations engaged in this space.

Chapter 13 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix that provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1.Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Classification of Vaccines: Based on Type Active Ingredient
    • 3.2.1. Live, Attenuated Vaccines
    • 3.2.2. Inactivated Vaccines
    • 3.2.3. Subunit Vaccines
    • 3.2.4. Toxoid Vaccines
    • 3.2.5. DNA Vaccines
  • 3.3. Vaccine Formulations: Key Components
    • 3.3.1. Adjuvants
  • 3.4. Vaccine Development and Manufacturing
    • 3.4.1. Identification of the Antigen and Manufacturing Process Development
    • 3.4.2. Manufacturing Process
      • 3.4.2.1. Upstream Process
        • 3.4.2.1.1. Bacterial Expression Systems
        • 3.4.2.1.2. Yeast Expression Systems
        • 3.4.2.1.3. Insect Expression System
        • 3.4.2.1.4. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
        • 3.4.2.1.5. Mammalian Expression Systems
        • 3.4.2.1.6. Plant Expression Systems
        • 3.4.2.1.7. Avian Expression Systems
      • 3.4.2.2. Downstream Process
      • 3.4.2.3. Formulation and Fill/Finish
    • 3.4.3. Clinical Development and Approval
  • 3.5. Contract Manufacturing: Definition
    • 3.5.1. Vaccine Contract Manufacturing: Addressing an Unmet Need
    • 3.5.2. Vaccine Contract Manufacturing: Commonly Outsourced Operations
    • 3.5.3. Vaccine Contract Manufacturing: Selecting a CMO Partner
    • 3.5.4. Vaccine Contract Manufacturing: Risk Factors and Challenges

4. COMPETITIVE LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Analysis by Region
  • 4.3. Analysis by Scale of Operation
  • 4.4. Analysis by Expression Systems
  • 4.5. Analysis by Manufacturing Capabilities

5. VACCINE CONTRACT MANUFACTURING: DEVELOPED REGIONS

  • 5.1. Chapter Overview
  • 5.2. One Stop Shops: A Growing Trend in Vaccine Contract Manufacturing
  • 5.3. Vaccine Outsourcing in the US
  • 5.4. Vaccine Contract Manufacturing Market in the US, 2016 - 2026
  • 5.5. Vaccine Contract Manufacturing Market in the US, 2016 - 2026: Distribution by Type of Expression Systems Used
  • 5.6. Leading Vaccine CMOs in the US
    • 5.6.1. Albany Molecular Research (AMRI) / OSO Biopharmaceuticals Manufacturing (OsoBio)
      • 5.6.1.1. Company Overview
      • 5.6.1.2. Vaccine-related Service Portfolio
        • 5.6.1.2.1. Regulatory Support and Quality Assurance
        • 5.6.1.2.2. Vaccine Manufacturing Infrastructure
      • 5.6.1.3. Financial Performance
      • 5.6.1.4. Recent Developments
        • 5.6.1.4.1. Partnerships
        • 5.6.1.4.2. Awards and Recognition
        • 5.6.1.4.3. Expansions
    • 5.6.2. Catalent
      • 5.6.2.1. Company Overview
      • 5.6.2.2. Vaccine-related Service Portfolio
        • 5.6.2.2.1. Cell Line Development
        • 5.6.2.2.2. Clinical Manufacturing
        • 5.6.2.2.3. Analytical, Clinical Supply Services
        • 5.6.2.2.4. Regulatory Services
        • 5.6.2.2.5. Vaccine Manufacturing Facilities
          • 5.6.2.2.5.1. Swindon, United Kingdom
          • 5.6.2.2.5.2. Neder-Over-Heembeek, Belgium
          • 5.6.2.2.5.3. Kansas City, Missouri
      • 5.6.2.3. Financial Performance
      • 5.6.2.4. Recent Developments
        • 5.6.2.4.1. Partnerships
        • 5.6.2.4.2. Funding Instances and Expansions
    • 5.6.3. Charles River Laboratories
      • 5.6.3.1. Company Overview
      • 5.6.3.2. Vaccine-related Service Portfolio
        • 5.6.3.2.1. Vaccine Development Services
        • 5.6.3.2.2. Vaccine Manufacturing Services
        • 5.6.3.2.3. Avian Vaccine Services
      • 5.6.3.3. Financial Performance
      • 5.6.3.4. Recent Developments
        • 5.6.3.4.1. Partnerships
        • 5.6.3.4.2. Awards and Recognition
        • 5.6.3.4.3. Expansions
    • 5.6.4. Lonza
      • 5.6.4.1. Company Overview
      • 5.6.4.2. Vaccine-related Service Portfolio
        • 5.6.4.2.1. Process Development and Optimization
        • 5.6.4.2.2. Commercial Manufacturing
        • 5.6.4.2.3. Aseptic Fill/Finish
        • 5.6.4.2.4. Other Services
      • 5.6.4.3. Financial Performance
      • 5.6.4.4. Recent Developments
        • 5.6.4.4.1. Partnerships
        • 5.6.4.4.2. Expansions
    • 5.6.5. Meridian Life Science (MLS)
      • 5.6.5.1. Company Overview
      • 5.6.5.2. Vaccine-related Service Portfolio
        • 5.6.5.2.1. Vaccine Manufacturing Facility at Memphis, Tennessee
          • 5.6.5.2.1.1. Cell and Virus Banking
          • 5.6.5.2.1.2. Process development and Scale-up Services
          • 5.6.5.2.1.3. Formulation Development and Fill/finish
          • 5.6.5.2.1.4. Regulatory Support
          • 5.6.5.2.1.5. Other Services and Facilities
      • 5.6.5.3. Financial Performance
      • 5.6.5.4. Recent Developments
        • 5.6.5.4.1. Partnerships
        • 5.6.5.4.2. Awards and Recognition
        • 5.6.5.4.3. Expansions
    • 5.6.6. SAFC (A Unit of Sigma-Aldrich Corporation)
      • 5.6.6.1. Company Overview
      • 5.6.6.2. Vaccine-related Manufacturing Services
        • 5.6.6.2.1. cGMP Cell and Virus Banking
        • 5.6.6.2.2. Process Development
        • 5.6.6.2.3. Biorepository Services
        • 5.6.6.2.4. Contract Manufacturing Support Services
        • 5.6.6.2.5. Vaccine Manufacturing Capabilities
          • 5.6.6.2.5.1. Carlsbad Facility
      • 5.6.6.3. Financial Performance
      • 5.6.6.4. Recent Developments
        • 5.6.6.4.1. Partnerships
        • 5.6.6.4.2. Awards and Recognition
        • 5.6.6.4.3. Expansions
  • 5.7. Vaccine Outsourcing in Europe
  • 5.8. Vaccine Contract Manufacturing Market in Europe, 2016 - 2026
  • 5.9. Vaccine Contract Manufacturing Market in Europe, 2016 - 2026: Distribution by Type of Expression Systems Used
  • 5.10. Leading Vaccine CMOs in Europe
    • 5.10.1. Cobra Biologics
      • 5.10.1.1. Company Overview
      • 5.10.1.2. Vaccine-related Service Portfolio
        • 5.10.1.2.1. DNA Vaccines and DNA based Services
        • 5.10.1.2.2. Viral Vaccines and Virus based Services
        • 5.10.1.2.3. Other Services
      • 5.10.1.3. Recent Developments
        • 5.10.1.3.1. Partnerships
        • 5.10.1.3.2. Funding Instances and Expansions
    • 5.10.2. Eurogentec
      • 5.10.2.1. Company Overview
      • 5.10.2.2. Vaccine-related Service Portfolio
        • 5.10.2.2.1. Manufacturing Services
        • 5.10.2.2.2. Analytical and Regulatory Support
        • 5.10.2.2.3. Other Services
      • 5.10.2.3. Recent Developments
        • 5.10.2.3.1. Partnerships
    • 5.10.3. IDT Biologika
      • 5.10.3.1. Company Overview
      • 5.10.3.2. Vaccine-related Service Portfolio
        • 5.10.3.2.1. Development Services
        • 5.10.3.2.2. Manufacturing Services
        • 5.10.3.2.3. Fill/Finish Operations
        • 5.10.3.2.4. Supporting Services
          • 5.10.3.2.4.1. Labeling and Packaging
          • 5.10.3.2.4.2. Storage
          • 5.10.3.2.4.3. Quality Control
        • 5.10.3.2.5. Vaccine Manufacturing Facilities
          • 5.10.3.2.5.1. Riems, Germany
          • 5.10.3.2.5.2. Dessau, Germany
          • 5.10.3.2.5.3. Rockville, Maryland
      • 5.10.3.3. Financial Performance
      • 5.10.3.4. Recent Developments
        • 5.10.3.4.1. Partnerships
        • 5.10.3.4.2. Awards and Recognition
        • 5.10.3.4.3. Expansions
    • 5.10.4. SynCo Bio Partners
      • 5.10.4.1. Company Overview
      • 5.10.4.2. Vaccine-related Service Portfolio
        • 5.10.4.2.1. Process Development
          • 5.10.4.2.1.1. Microbial Process Development
          • 5.10.4.2.1.2. Product Development for Live Biotherapeutics
        • 5.10.4.2.2. Analytical and Quality Control Services
        • 5.10.4.2.3. GMP Manufacturing
        • 5.10.4.2.4. Aseptic Filling and Lyophilization Services
        • 5.10.4.2.5. Quality Assurance and Regulatory Support
      • 5.10.4.3. Recent Developments
        • 5.10.4.3.1. Partnerships
        • 5.10.4.3.2. Awards and Recognition
        • 5.10.4.3.3. Expansions

6. VACCINE CONTRACT MANUFACTURING: EMERGING REGIONS

  • 6.1. Chapter Overview
  • 6.2. Vaccine Contract Manufacturing in China
    • 6.2.1. Contract Manufacturing in China: Regulatory Landscape
    • 6.2.2. Contract Manufacturing in China: Key Challenges
    • 6.2.3. Vaccine Contract Manufacturing in China: Investments and Business Expansions
  • 6.3. Vaccine Contract Manufacturing Market in China, 2016 - 2026
  • 6.4. Vaccine Contract Manufacturing Market in China, 2016 - 2026: Distribution by Type of Expression Systems Used
  • 6.5. Leading Vaccine CMOs in China
    • 6.5.1. GreenPak Biotech
      • 6.5.1.1. Company Overview
      • 6.5.1.2. Vaccine-related Service Portfolio
    • 6.5.2. Hong Kong Institute of Biotechnology
      • 6.5.2.1. Company Overview
      • 6.5.2.2. Vaccine-related Service Portfolio
        • 6.5.2.2.1. The Biologics Unit at the Hong Kong Institute of Biotechnology
        • 6.5.2.2.2. Vaccine Contract Manufacturing
    • 6.5.3. WuXi AppTec
      • 6.5.3.1. Company Overview
      • 6.5.3.2. Vaccine-related Service Portfolio
        • 6.5.3.2.1. Discovery and Early Diagnostic Testing Services
        • 6.5.3.2.2. Non-Clinical Services
        • 6.5.3.2.3. Support Services
        • 6.5.3.2.4. Manufacturing Services
        • 6.5.3.2.5. Vaccine Testing
      • 6.5.3.3. Financial Performance
      • 6.5.3.4. Recent Developments
        • 6.5.3.4.1. Collaborations and Mergers
  • 6.6. Vaccine Contract Manufacturing in India
    • 6.6.1. Contract Manufacturing in India: Regulatory Landscape
    • 6.6.2. Contract Manufacturing in India: Key Challenges
  • 6.7. Vaccine Contract Manufacturing Market in India, 2016 - 2026
  • 6.8. Vaccine Contract Manufacturing Market in India, 2016 - 2026: Distribution by Type of Expression Systems Used
  • 6.9. Leading Vaccine CMOs in India
    • 6.9.1. Bharat Biotech
      • 6.9.1.1. Company Overview
      • 6.9.1.2. Vaccine-related Service Portfolio
      • 6.9.1.3. Financial Performance
      • 6.9.1.4. Recent Developments
      • 6.9.1.4.1. Partnerships
      • 6.9.1.4.2. Awards and Fundings
    • 6.9.2. Biological E
      • 6.9.2.1. Company Overview
      • 6.9.2.2. Vaccine-related Service Portfolio
        • 6.9.2.2.1. Complete Service Portfolio
      • 6.9.2.3. Financial Performance
      • 6.9.2.4. Recent Developments
        • 6.9.2.4.1. Partnerships
        • 6.9.2.4.2. Awards and Recognition
        • 6.9.2.4.3. Expansions

7. RECENT DEVELOPMENTS

  • 7.1. Chapter Overview
  • 7.2. Vaccine Contract Manufacturing Market: Partnerships
    • 7.2.1. Vaccine Contract Manufacturing Market: Growing Trend of Partnerships
    • 7.2.2. Vaccine Contract Manufacturing Market: Analysis by Type of Partnership
    • 7.2.3. Vaccine Contract Manufacturing Market: Analysis by Relevance of Partnership
  • 7.3. Vaccine Contract Manufacturing Market: Capability Expansions

8. MARKET FORECAST

  • 8.1. Chapter Overview
  • 8.2. Forecast Methodology
  • 8.3. Vaccine Contract Manufacturing Market. 2016 - 2026
  • 8.4. Vaccine Contract Manufacturing Market: Regional Distribution
  • 8.5. Vaccine Contract Manufacturing Market: Distribution by Type of Expression Systems Used

9. SWOT ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Strengths
  • 9.3. Weaknesses
  • 9.4. Opportunities
  • 9.5. Threats

10. FUTURE TRENDS

  • 10.1. Chapter Overview
  • 10.2. Innovative Technologies to Drive Growth
  • 10.3. The Advent of VLPs
  • 10.4. Cell Culture Media Optimization
  • 10.5. Growing Demand likely to Spur Additional Investments
  • 10.6. Shift toward Strategic Partnering
  • 10.7. Acquisition of Smaller Businesses

11. CONCLUSION

12. INTERVIEW TRANSCRIPTS

13. APPENDIX I TABULATED DATA

14. APPENDIX II LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1 Vaccine Manufacturing: Common Processes
  • Figure 3.2 Types of Third Party Service Providers in the Pharmaceutical Industry
  • Figure 3.3 Commonly Outsourced Vaccine Development Operations
  • Figure 4.1 Vaccine CMOs: Geographical Presence by Country
  • Figure 4.2 Vaccine CMOs: Geographical Presence by Region
  • Figure 4.3 Vaccine CMOs: Distribution by Scale of Operation
  • Figure 4.4 Vaccine CMOs: Distribution by Expression Systems
  • Figure 4.5 Vaccine CMOs: Availability of Manufacturing Capabilities
  • Figure 5.1 Vaccine Contract Manufacturing Market in the US: Growth Drivers and Challenges
  • Figure 5.2 Vaccine Contract Manufacturing Market in the US, 2016 - 2026: Base Scenario (USD Billion)
  • Figure 5.3 Vaccine Contract Manufacturing Market in the US, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
  • Figure 5.4 AMRI (OsoBio): Vaccine-related Service Portfolio
  • Figure 5.5 AMRI (OsoBio): Annual Revenues, FY 2011 - Q1 2016 (USD Million)
  • Figure 5.6 AMRI (OsoBio): Revenues by Business Segments, FY 2015 (USD Million)
  • Figure 5.7 Catalent: Vaccine-related Service Portfolio
  • Figure 5.8 Catalent: Annual Revenues, FY 2011 - FY 2015 (USD Billion)
  • Figure 5.9 Catalent: Revenues by Business Segments, FY 2015 (USD Billion)
  • Figure 5.10 Charles River Laboratories: Products and Services
  • Figure 5.11 Charles River Laboratories: Annual Revenues, FY 2011 - FY 2015 (USD Billion)
  • Figure 5.12 Charles River Laboratories: Revenues by Business Segments, FY 2015 (USD Billion)
  • Figure 5.13 Lonza: Vaccine-related Service Portfolio
  • Figure 5.14 Lonza: Annual Revenues, FY 2011 - FY 2015 (CHF Billion)
  • Figure 5.15 Lonza: Revenues by Business Segments, 2015 (CHF Billion)
  • Figure 5.16 MLS: Process Development and Scale-up Services
  • Figure 5.17 MLS: Annual Revenues, FY 2011 - FY 2015 (USD Million)
  • Figure 5.18 MLS: Revenues by Business Segments, FY 2015 (USD Million)
  • Figure 5.19 SAFC: Contract Manufacturing Services and Solutions
  • Figure 5.20 SAFC: Contract Manufacturing Support Services
  • Figure 5.21 SAFC Carlsbad Facility: Vaccine Manufacturing Services
  • Figure 5.22 Sigma-Aldrich: Annual Revenues, FY 2010 - FY 2014 (USD Billion)
  • Figure 5.23 Sigma-Aldrich: Revenues by Business Segments, FY 2014 (USD Billion)
  • Figure 5.24 Vaccine Contract Manufacturing in Europe: Growth Drivers and Challenges
  • Figure 5.25 Vaccine Contract Manufacturing Market in Europe, 2016 - 2026: Base Scenario (USD Billion)
  • Figure 5.26 Vaccine Contract Manufacturing Market in Europe, 2016 - 2026: Distribution byType of Expression Systems Used (USD Billion)
  • Figure 5.27 Eurogentec: Manufacturing Technologies and Capabilities
  • Figure 5.28 IDT Biologika: Vaccine-related Service Portfolio
  • Figure 5.29 IDT Biologika: Annual Revenues, FY 2011 - FY 2015 (EUR Million)
  • Figure 5.30 SynCo Bio Partners: Vaccine-related Service Portfolio
  • Figure 6.1 Contract Manufacturing Market in China: Key Growth Drivers
  • Figure 6.2 Vaccine Contract Manufacturing Market in China, 2016 - 2026: Base Scenario (USD Billion)
  • Figure 6.3 Vaccine Contract Manufacturing Market in China, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
  • Figure 6.4 Hong Kong Institute of Biotechnology: Service Portfolio
  • Figure 6.5 WuXi AppTec: Vaccine Development Services
  • Figure 6.6 WuXi AppTec: Vaccine Testing Services
  • Figure 6.7 Contract Manufacturing Market in India: Key Drivers and Concerns
  • Figure 6.8 Vaccine Contract Manufacturing Market in India, 2016 - 2026: Base Scenario (USD Billion)
  • Figure 6.9 Vaccine Contract Manufacturing Market in India, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
  • Figure 6.10 Biological E: Vaccine-related Service Portfolio
  • Figure 7.1 Vaccine Contract Manufacturing Market: Cumulative Trend of Partnerships, Pre 2009 - 2016
  • Figure 7.2 Vaccine Contract Manufacturing Market: Distribution by Type of Partnership
  • Figure 7.3 Vaccine Contract Manufacturing Market: Distribution by Relevance of Partnership
  • Figure 8.1 Share of Contract Manufacturers in the Vaccines Market
  • Figure 8.2 Vaccine Market, 2016 - 2026 (USD Billion)
  • Figure 8.3 Vaccine Manufacturing Market, 2016 - 2026: Base Scenario (USD Billion)
  • Figure 8.4 Vaccine Contract Manufacturing Market, 2016 - 2026: Regional Distribution (USD Billion)
  • Figure 8.5 Vaccine Contract Manufacturing Market: Regional Distribution 2016, 2021 and 2026
  • Figure 8.6 Vaccine Contract Manufacturing Market, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
  • Figure 9.1 Vaccines in the Development Pipeline: By Therapeutic Area

List of Tables

  • Table 3.1 Vaccines and Small Molecule Drugs: Key Differences
  • Table 3.2 Vaccines: Classification Based on Method of Development
  • Table 3.3 Live Attenuated Vaccines: Commonly Reported Adverse Events
  • Table 3.4 Inactivated Vaccines: Commonly Reported Adverse Events
  • Table 3.5 Subunit Vaccines: Commonly Reported Adverse Events
  • Table 3.6 Toxoid Vaccines: Commonly Reported Adverse Events
  • Table 3.7 Vaccine Excipients and their Functions
  • Table 4.1 Vaccine CMOs: Geographical Distribution
  • Table 4.2 Vaccine CMOs: Overview of Scales of Operation
  • Table 4.3 Vaccine CMOs: Types of Expression Systems Used
  • Table 4.4 Vaccine CMOs: Manufacturing Capabilities
  • Table 5.1 Companies Providing One Stop Shop Services
  • Table 5.2 AMRI (OsoBio): Partnerships
  • Table 5.3 Catalent: Biologics Manufacturing and Laboratory Facilities
  • Table 5.4 Catalent: Partnerships
  • Table 5.5 Charles River Laboratories: Partnerships
  • Table 5.6 Lonza: Partnerships
  • Table 5.7 MLS: Partnerships
  • Table 5.8 SAFC: Partnerships
  • Table 5.9 Cobra Biologics: Production Facilities
  • Table 5.10 Cobra Biologics: Partnerships
  • Table 5.11 Cobra Biologics: Funding Instances
  • Table 5.12 Eurogentec: Partnerships
  • Table 5.13 IDT Biologika: Partnerships
  • Table 5.14 SynCo Bio Partners: Partnerships
  • Table 6.1 Hong Kong Institute of Biotechnology: Vaccine Contract Manufacturing Services
  • Table 6.2 WuXi AppTec: Biologics Development and Manufacturing Services
  • Table 6.3 Bharat Biotech: Partnerships
  • Table 6.4 Biological E: Partnerships
  • Table 7.1 Vaccine Contract Manufacturing Market: Partnerships
  • Table 9.1 Vaccine Contract Manufacturing Market: SWOT Analysis
  • Table 13.1 Vaccine CMOs: Geographical Presence by Country
  • Table 13.2 Vaccine CMOs: Geographical Presence by Region
  • Table 13.3 Vaccine CMOs: Distribution by Scale of Operation
  • Table 13.4 Vaccine CMOs: Distribution by Expression Systems
  • Table 13.5 Vaccine CMOs: Availability of Manufacturing Capabilities
  • Table 13.6 Vaccines Contract Manufacturing Market in the US, 2016 - 2026: Base Scenario (USD Billion)
  • Table 13.7 Vaccine Contract Manufacturing Market in the US, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
  • Table 13.8 AMRI (OsoBio): Annual Revenues, FY 2011 - Q1 2016 (USD Million)
  • Table 13.9 AMRI (OsoBio): Revenues by Business Segments, FY 2015 (USD Million)
  • Table 13.10 Catalent: Annual Revenues, FY 2011 - FY 2015 (USD Billion)
  • Table 13.11 Catalent: Revenues by Business Segments, FY 2015 (USD Billion)
  • Table 13.12 Charles River Laboratories: Annual Revenues, FY 2011 - FY 2015 (USD Billion)
  • Table 13.13 Charles River Laboratories: Revenues by Business Segments, FY 2015 (USD Billion)
  • Table 13.14 Lonza: Annual Revenues, FY 2011 - FY 2015 (CHF Billion)
  • Table 13.15 Lonza: Revenues by Business Segments, 2015 (CHF Billion)
  • Table 13.16 MLS: Annual Revenues, FY 2011 - FY 2015 (USD Million)
  • Table 13.17 MLS: Revenues by Business Segments, FY 2015 (USD Million)
  • Table 13.18 Sigma-Aldrich: Annual Revenues, FY 2010 - FY 2014 (USD Billion)
  • Table 13.19 Sigma-Aldrich: Revenues by Business Segments, FY 2014 (USD Billion)
  • Table 13.20 Vaccines Contract Manufacturing Market in Europe, 2016 - 2026: Base Scenario (USD Billion)
  • Table 13.21 Vaccine Contract Manufacturing Market in Europe, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
  • Table 13.22 IDT Biologika: Annual Revenues, FY 2011 - FY 2015 (EUR Million)
  • Table 13.23 Vaccines Contract Manufacturing Market in China, 2016 - 2026: Base Scenario (USD Billion)
  • Table 13.24 Vaccine Contract Manufacturing Market in China, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
  • Table 13.25 Vaccines Contract Manufacturing Market in India, 2016 - 2026: Base Scenario (USD Billion)
  • Table 13.26 Vaccine Contract Manufacturing Market in India, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
  • Table 13.27 Vaccine Contract Manufacturing Partnerships: Cumulative Trend, Pre 2009 -2016
  • Table 13.28 Vaccine Contract Manufacturing Partnerships: Distribution by Type of Partnership
  • Table 13.29 Vaccine Contract Manufacturing Partnerships: Distribution by Relevance of Partnership
  • Table 13.30 Vaccine Market, 2016 - 2026 (USD Billion)
  • Table 13.31 Vaccine Manufacturing Market, 2016 - 2026: Base Scenario (USD Billion)
  • Table 13.32 Vaccine Contract Manufacturing Market, 2016 - 2026: Regional Distribution (USD Billion)
  • Table 13.33 Vaccine Contract Manufacturing Market, 2016 - 2026: Regional Distribution 2016, 2021 and 2026
  • Table 13.34 Vaccine Contract Manufacturing Market, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)

Listed Companies

The following companies have been mentioned in the report.

  • 1. 3P Biopharmaceuticals
  • 2. ABL
  • 3. Acambis
  • 4. Accugenix
  • 5. Actavis
  • 6. Advanced BioScience Laboratories
  • 7. Advaxis
  • 8. Aeras
  • 9. Air Force Hospital, Guangzhou
  • 10. AJ Biologics
  • 11. Albany Molecular Research (AMRI)
  • 12. Alexion
  • 13. Algonomics
  • 14. Altaris Capital Partner
  • 15. AmbioPharm
  • 16. AnaSpec
  • 17. Aptuit
  • 18. Association for Assessment and Accreditation of Laboratory Animal Care
  • 19. Association Sportive du Golf Club Val de l'Indre
  • 20. Australian Therapeutic Goods Administration
  • 21. Avid Bioservices
  • 22. Bachem
  • 23. Batavia Biosciences
  • 24. Bavarian Nordic
  • 25. Baxter BioPharma Solutions
  • 26. BD Biosciences
  • 27. Benchmark Vaccines
  • 28. Bharat Biotech
  • 29. Bill and Melinda Gates Foundation
  • 30. BioCell Corporation
  • 31. Biocon
  • 32. BioConnections
  • 33. BioConvergence
  • 34. Biofabri
  • 35. Bioline Group of Companies
  • 36. Biological E
  • 37. BioMARC
  • 38. Biomay
  • 39. Biomedical Advanced Research and Development Authority
  • 40. BioMotiv
  • 41. Biopharmaceutical Development Program - Frederick National Laboratory for Cancer Research
  • 42. BioReliance Holdings
  • 43. BioTechnique
  • 44. Biotechnology and Biological Sciences Research Council
  • 45. Biotechnology and Biological Sciences Research Council
  • 46. Biovest International
  • 47. Boehringer Ingelheim
  • 48. Boehringer Ingelheim BioXcellence™
  • 49. Bristol-Myers Squibb
  • 50. Bryllan
  • 51. CALIXAR
  • 52. Canadian Animal Health Institute
  • 53. Canadian Council on Animal Care
  • 54. Catalent
  • 55. Catalent Pharma Solutions
  • 56. Celsis International
  • 57. Centers for Disease Control and Prevention
  • 58. CEPiA Sanofi (Transgene)
  • 59. Cetus Corporation
  • 60. CEVEC Pharmaceuticals
  • 61. Charles River Laboratories International
  • 62. Chimera Biotec
  • 63. China Agricultural University
  • 64. China National Biotec Group
  • 65. Chinese Center for Disease Control and Prevention
  • 66. Cobra Biologics
  • 67. Cook Pharmica
  • 68. Council of the Chinese University of Hong Kong
  • 69. Crucell Sweden
  • 70. Cytovance Biologics
  • 71. Daiichi Sankyo
  • 72. Deltamune
  • 73. Developing Countries Vaccine Manufacturers Network
  • 74. Dr. Reddy's Laboratories
  • 75. Emergent BioSolutions
  • 76. Engineering and Physical Sciences Research Council
  • 77. Eubiologics
  • 78. Eurogentec
  • 79. European Medicines Agency
  • 80. Federation of Indian Chambers of Commerce and Industry
  • 81. Florida Biologix
  • 82. Friedrich-Loeffler-Institut
  • 83. FUJIFILM Diosynth Biotechnologies
  • 84. Gallant Custom Laboratories
  • 85. Gamma Vaccines
  • 86. Genentech
  • 87. GENEWIZ
  • 88. GlaxoSmithKline
  • 89. Global Alliance for Vaccines and Immunizations
  • 90. GNH India
  • 91. Goodwin Biotechnology
  • 92. Government of India's Universal Immunisation Programme
  • 93. Grand River Aseptic Manufacturing
  • 94. GreenPak Biotech
  • 95. Guangxi Veterinary Research Institute
  • 96. Haffkine Institute
  • 97. HALIX
  • 98. Harbin Veterinary Research Institute
  • 99. Harbin Veterinary Research Institute, China
  • 100. HK Jockey Club Charities Trust
  • 101. HLL Biotech
  • 102. Hong Kong Institute of Biotechnology
  • 103. IDT Biologika
  • 104. Immune Design
  • 105. Immune Targeting Systems
  • 106. ImmunoSite Technologies
  • 107. ImVisioN Therapeutics
  • 108. Index Ventures
  • 109. Indian Council of Medical Research
  • 110. Indian Immunologicals
  • 111. Infectious Disease Research Institute
  • 112. Innovation & Technology Commission, HKSAR Government, China
  • 113. Integrity Bio
  • 114. Intercell
  • 115. International Medica Foundation
  • 116. International Society for Pharmaceutical Engineering
  • 117. Interros Group
  • 118. Inviragen
  • 119. Irvine Pharmaceutical Services
  • 120. Jubilant HollisterStier
  • 121. KABS Pharmaceutical Services
  • 122. Kaneka Corporation
  • 123. KBI Biopharma
  • 124. LigoCyte Pharmaceuticals
  • 125. Lonza
  • 126. Magellan Biosciences
  • 127. MassBiologics
  • 128. Medicago
  • 129. Mefar Ilac (Birgi Mefar Group)
  • 130. Meridian Life Science
  • 131. Ministry of Health & Family Welfare, Government of India
  • 132. Mitsubishi Gas Chemical Company
  • 133. Mitsubishi Tanabe Pharma Corporation
  • 134. Moderna Therapeutics
  • 135. Mymetics Corporation
  • 136. National Avian Influenza Reference Laboratory
  • 137. National Heart, Lung and Blood Institute
  • 138. National Institutes of Allergy and Infectious Diseases
  • 139. Norwegian Institute of Public Health
  • 140. Novartis
  • 141. Novasep
  • 142. Novavax
  • 143. NPO Petrovax Pharm
  • 144. NTC
  • 145. OctoPlus
  • 146. Okairos
  • 147. Oncotest
  • 148. Organization for Economic Cooperation and Development
  • 149. OSO Biopharmaceuticals Manufacturing (OsoBio)
  • 150. Pacific GMP
  • 151. Panacea Biotec
  • 152. Paragon Bioservices
  • 153. PATH
  • 154. Pfenex
  • 155. Pfizer
  • 156. Pfizer CentreOne
  • 157. Pharmapak
  • 158. PharmaSynth
  • 159. Premas Biotech
  • 160. Prime European Therapeuticals
  • 161. ProBioGen
  • 162. Protagen
  • 163. PX'Therapeutics
  • 164. QuiaPEG
  • 165. RAFAGEN
  • 166. Recipharm
  • 167. Richter-Helm
  • 168. Riemser Pharma
  • 169. SAFC
  • 170. Sanofi
  • 171. Sanofi Pasteur
  • 172. Sartorius Stedim Biotech
  • 173. Serum Institute
  • 174. Shandong Zhaoxin Bio-tech Company
  • 175. Shanghai Laboratory Animal Commission
  • 176. ShangPharma
  • 177. Sigma-Aldrich
  • 178. South China Agricultural University
  • 179. Statens Serum Institut
  • 180. Stellar Biotechnologies
  • 181. Swiss State Secretariat Education, Research and Innovation
  • 182. SynCo Bio Partners
  • 183. Technology Strategy Board
  • 184. Temasek Life Sciences Ventures
  • 185. The College of Animal Science and Technology, Sichuan Agricultural University, China
  • 186. Thermo Fisher Scientific
  • 187. Tianjin CanSino Biotechnology
  • 188. UK Medicines Control Agency
  • 189. Unitech Pharma Group
  • 190. United States Food and Drug Association
  • 191. Univercells
  • 192. University of Maryland
  • 193. University of Oxford
  • 194. University of Pennsylvania
  • 195. Upperton
  • 196. Vaccibody
  • 197. Vacsera
  • 198. Valneva
  • 199. Vetter Pharma International
  • 200. VGXI
  • 201. Vibalogics
  • 202. Vivalis
  • 203. Vybion (Recombinant Protein Technologies and Products)
  • 204. Waisman Biomanufacturing
  • 205. Walter Reed Army Institute of Research - Pilot Bioproduction Facility
  • 206. Wellcome Trust
  • 207. WIL Research
  • 208. World Trade Organization
  • 209. WuXi AppTec
  • 210. Zoetis
Back to Top